Odedina, Folakemi T.

ABSTRACT Purpose This study assesses the association between colorectal cancer (CRC) screening and a validated, housing-based measure of individual-level socioeconomic status (SES, called HOUSES hereafter) within rural communities and determines whether HOUSES-integrated geospatial analysis can be used to tailor interventions. Methods We used CRC screening data from a subset of Mayo Clinic Midwest patients living in cities without ready access to routine care in the Mayo Clinic Health System in 2019 to represent rural communities. At the individual level, we assessed the association between CRC screening rates and the HOUSES index, adjusting for age, sex, race/ethnicity, comorbidity, distance from home address to clinic, and area deprivation index, using a multilevel mixed-effects logistic regression model. Additionally, we conducted geospatial analysis to examine the correlation between hotspots of 1) lower CRC screening rates and 2) lower SES of the subject population (HOUSES quartile 1). Findings Among 34,489 individuals (median age 64.0 years, 52.4% female), those with the lowest SES (HOUSES Q1) had 37% lower odds of being CRC screening adherent than those with the highest SES (HOUSES Q4) (adj. OR [95% CI]: 0.63 [0.58-0.69]). In the 14 identified HOUSES Q1 hotspots, there was a significant correlation in counts of HOUSES Q1 and low CRC screening (correlation coefficient=0.81). Conclusion Lower SES was significantly associated with lower CRC screening among rural populations. HOUSES-enabled geospatial analysis identified geographic hotspots with lower CRC screening rates for targeted interventions to address disparities in CRC screening in rural communities. HOUSES may be a useful digital tool for cancer preventive care and research.

Abstract Background: Black men carry a disproportionate prostate cancer (CaP) burden and often experience significant psychosocial distress at the point of prostate cancer diagnosis (PPCD). Many report emotional shock, uncertainty, and limited access to culturally competent guidance, which can negatively affect treatment decisions and long-term survivorship. To address these needs, we developed the PPCD Virtual Reality Assistant (ViRA), an immersive, AI-enabled intervention co-designed with Black CaP survivors. ViRA delivers tailored psycho-oncology support, emotional guidance, and navigation of social determinants of health (SDOH) within virtual reality environments. This study evaluated the feasibility, acceptability, and usability of the PPCD ViRA (NCT06535802). Methods: ViRA was developed through a structured, seven-step co-design process with survivors, integrating mobile immersive technologies, SDOH navigation, and culturally grounded psycho-oncology content. Personalization was enabled through AI-driven predictive analytics and a recommendation engine. Alpha testing assessed initial usability and acceptability among 10 participants (seven team members and three Black CaP survivors). Beta testing with 24 Black men in Florida examined feasibility and preliminary efficacy. Results: A demonstration of ViRA is available (https://www.youtube.com/watch?v=1mI-HS5R6sk). Alpha testing indicated strong usability, positive emotional engagement, and clear promise for enhancing support at the PPCD. In Beta testing, participants varied in age; most were married (58.3%), held a bachelor’s degree (45.8%), were retired (45.8%), and had a family history of cancer (83.3%). ViRA use was associated with increased engagement and reduced distress across participants. Overall, 74% rated ViRA as “excellent,” while the remainder rated it as “good” or “very good.” More than 90% reported being “very satisfied,” with the rest indicating satisfaction. Conclusions: Findings demonstrate high feasibility, acceptability, and cultural relevance of the PPCD ViRA for supporting Black men at diagnosis. Lessons learned highlight the need for culturally embedded design, emotional timing, community co-creation, flexible delivery formats, and strong community partnerships to advance digital health equity. The refinement and larger-scale validation to establish clinical utility and readiness for implementation is ongoing (NCT07126548). Citation Format: Folakemi T. Odedina, Che Ngufor, Christopher Williams, Mary Ellen Young, Floyd Willis, Adam M. Kase, Arnold Merriweather, Emelina Asto-Flores, Dee M. Glaser-Boivin, Jada Melton, Monica L. Albertie, Michelle Fudge, Quincy Wimberly, Inclusive Cancer Care Research Equity (iCCaRE) Consortium, Prostate Cancer Transatlantic Consortium (CaPTC). Novel application of the iCCaRE consortium virtual reality assistant (ViRA) to support Black men at the point of prostate cancer diagnosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6306.

Abstract Introduction: COE has become the gold standard in addressing health disparities. COE’s value is emphasized by NIH and leading cancer-related organizations e.g., AACR. The Alliance for COE (The Alliance) mission is to advance the art, science, and impact of COE; promote community health and wellness; and reduce cancer burden and disparities. Methods: This abstract builds on the Alliance’s Science of Community Outreach and Engagement (SoCOE) Conference a NCI R13 funded series. SoCOE Conference is organized by 10 NCI-designated Cancer Centers to provide a platform for COE academic-clinical-policy-community stakeholders to share best practices for solution-focused community responsive cancer prevention, diagnostics, therapeutics and survivorship research and practice. Results: > 500 researchers, clinicians, policymakers, healthcare administrators, with >12% being survivors and/or advocates, participated in our SoCOE Conferences. The delegates’ recommendations are: Decentralize who/entities that hold all the power in science and clinical research (trials). Communities hold valuable, necessary wisdom and resources to inform and guide science Include multisectoral partners early and always Community capacity building and compensation with gratitude Mentoring of junior COE researchers, clinicians, policymakers, healthcare administrators, survivors and advocates with humility is a must Develop virtual communities to share best practices across cancer centers and within regions Develop working groups to identify and explore commonalities across COE work in rural/urban, diverse/homogenous spaces Publish Science of COE papers on various topics related to COE Frameworks and evidenced-solutions Provide community reports on best practice guide that can be widely available to be shared locally and in-person, and digitally Partner and learn from COE teams working with other cultural/ethnic groups Attend to, measure and remedy societal/social drivers of health disparities that mirror barriers to care, and research engagement and participation. Discussion: Informed by our community advisory boards and the findings for our SoCOE Conferences, we present the pillars of the Alliance to tackle population cancer burden and disparities: Training future COE leaders/advocates, Advocating for public health policies/guidelines, Increasing access to cancer prevention and care that will also increase access to studies, Engaging and partnering with multisectoral stakeholders and communities, Building community capacity, Advancing COE science through catchment-relevant research, and Leading bi-directional communication and information and resource sharing between catchment area communities and cancer centers. The expectation and impact of COE can only be achieved if COE teams are valued, supported cancer center members with community advisory boards and community as cancer centers’ priority population. Citation Format: Kimlin Ashing, CHARNITA ZEIGLER-JOHNSON, Hayley S. Thompson, Kim Rhoads, Nadine Barrett, Lisa Carter Bawa, Timiya S. Nolan, Monica Baskin, Vanessa B. Sheppard, Marvella E. Ford, Erica Phillips, Lorna H. McNeill, Folakemi T. Odedina. Advancing the science, practice and impact of COE [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7577.

Abstract Background: Prostate cancer (PCa) is the leading cause of cancer-related deaths globally and disproportionately affects men of African ancestry. African men often present at younger ages and with more aggressive disease, and approximately half of the PCa risk has been attributed to genetic factors. Africa is the most genetically diverse region of the world, and even within the continent, populations show important differences in allele frequencies and patterns of pathogenic variation. Despite this diversity, African men remain underrepresented in genomic studies, creating significant gaps in knowledge that limit precision medicine efforts. Methods: A total of 182 prostate cancer patients were recruited from teaching hospitals in Benin, Côte d’Ivoire, Ghana, Kenya and Nigeria. 50 cancer susceptibility genes using the Aviseq ONCO50 panel and the Illumina MiSeq platform. Variant calling was performed using an in-house Snakemake workflow, followed by additional bioinformatic steps to distinguish true PMS2 variants from PMS2CL-related artifacts. Pathogenicity assessment relied on annotations from ClinVar and LOVD databases. Results: Pathogenic and likely pathogenic variants were detected in 31.3% of the study group identified in 26 genes. The five most frequently altered genes were RAD50, PTCH1, MSH6, MUTYH, and NF1. Nigerian patients accounted for 52.6 percent of all pathogenic variants, with recurrent alterations observed in MSH6, MUTYH, NF1, and PTCH1. In contrast, pathogenic BRCA1 and BRCA2 variants were observed primarily in patients from Kenya, Benin, and Côte d’Ivoire. Several frameshift, nonsense, and splice-site variants identified in this study have not been previously reported in African populations.[SR1] Conclusion: This study provides one of the most detailed assessments of inherited cancer susceptibility gene variants in African PCa patients. The findings reveal substantial regional variation in the spectrum of pathogenic variants and highlight population-specific genomic signatures that may contribute to the unequal burden of PCa in men of African ancestry. These data emphasize the importance of expanding genomic research efforts within Africa to strengthen precision oncology and reduce global PCa disparities. Citation Format: Abimbola F. Onyia, Freeman Okwuchi, Opeyemi C. De Campos, Sylvester Divine, Olutola Olasehinde, Ayinde Yahaya, Ayo Salako, Aminu Zakari, Iya Bassey, Nicholas Titiloye, Bernard Petershie, Isidore GANDAHO, Luc Brun, Tore Sanni, Safiatou Coulibaly, Noel Coulibaly, Michael Fakayode, Coulibaly Issoufou, Valérie Gbonon, Kouame Benjamin, Yao Evrard, Peter Coleman, Ayun Cassell, Victor Ajumbo, Lilac Wattanga, Benson Ochieng Nyambega, Folakemi T. Odedina, Solomon Rotimi. Targeted sequencing of common cancer susceptibility genes reveals germline variants in African prostate cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6289.

Abstract Background: Cancer survivorship requires significant contributions from family caregivers at home. This role can be burdensome because family members play a vital role in the physical, functional, and emotional well-being of patients diagnosed with cancer. Although optimum care throughout the care continuum requires significant caregiver support at home, family caregivers' contribution to survivorship care is usually neglected. We provide the preliminary outcomes of caregivers' challenges and experiences in providing care and survivorship support to Black cancer survivors. We also identified ways to provide support for family caregivers. Methods: This qualitative study obtained information from 8 caregivers who care for Black cancer survivors who have completed treatment in the United States. The study used a phenomenological design to obtain data from participants. In-depth interviews focused on participants' lived experiences caring for Black patients with cancer. The study captured caregivers' personal stories of how they dealt with diagnosis, feelings, emotions, reactions, understanding of the disease, prognosis, and treatment options and decision process, as well as survivorship of their care recipients. All interviews were video recorded and transcribed verbatim. The transcript of each participant's interview was reviewed, analyzed, and coded, with emerging themes interpreted. Results: The major cahllenges identified were (1) lack of knowledge of cancer, the disease and treatment course before the diagnoses; (2) home care burden, which include the challenges of combining care for a sick person at home with caring for other members of the family and taking care of domestic chores; (3) patient care navigation, including identifying healthcare professional for specialist care, adequate health insurances, scheduling doctors' appointment, transportation, insurance and treatment paperwork; (4) financial challenges, especially keeping up with job, family income reduction, increase out of pocket spendings, as well as expensive drugs and treatment co-pays. Most of the caregivers agreed that they neglected their personal health while caring for their care recipient. All caregivers wished they received more information and training on how to care for a patient with cancer. Possible solutions identified were care packets providing information on cancer and how to provide care at home, patient care navigation to social determinants of health and financial support programs, counselling for mental health and emotional support, peer support groups for caregivers, health checks, and a contact to call for support. Conclusion: Caring for cancer patients at home is very challenging; having a care packet and caregiving training is important to support survivorship and reduce the caregiving burden experienced by family caregivers. Citation Format: Opeyemi Oreoluwa Bolajoko, Jada Melton, Mary Ellen Young, Folakemi T. Odedina. Perspectives on cancer survivorship: Voices of family caregivers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1248.

Abstract Background: Despite the decline in overall mortality and incidence of cancer in the US population, the burden of cancer is still high, especially in underserved and under-researched populations. A major contributor to poor cancer outcomes is the absence of dedicated efforts utilizing scientifically rigorous approaches and implementation strategies to optimize participant enrollment and accrual in clinical trials. The Connecting Patient Populations to Clinical Trials (CP2CT) program implements innovative multilevel interventions to enhance clinical trial awareness and optimize referral pathways that facilitate patient enrollment. The CP2CT Data, Evaluation, and Coordinating Center (DECC) supports its data and evaluation activities, and coordinates a learning collaborative towards mitigating the key barriers of cancer burden in all populations. Methods: Using an implementation science-informed approach, the DECC deployed coordinated strategies over three years: (1) administrative structuring through streamlined governance, centralized reporting, and stakeholder integration; (2) data standardization via Common Data Elements (CDEs), a cross-network REDCap system, and a multi-institution Data Transfer Agreement (DTA); (3) evaluation infrastructure through a Network Logic Model, evaluation plan, standardized constructs, and a Process Evaluation Plan with tools; (4) learning supports through an internal website and expanded Speaker Series; and (5) site-level implementation facilitation through structured visits. Results: In collaboration with the CP2CT Network and NCI, the DECC’s achievements span four domains: (1) Administrative: built infrastructure, deployed centralized reporting platforms, coordinated key meetings, and strengthened community integration. (2) Data: standardized collection, secured network-wide data sharing through the DTA, enabled harmonized multi-site reporting, and advanced groundwork for interoperability and scientific value. (3) Program Evaluation: linked CP2CT activities to measurable outcomes through a Network-wide Logic Model, guided evaluation, established shared evaluation language, and launched a transferable Process Evaluation framework. (4) Learning Collaborative: developed a centralized resource hub, expanded the Speaker Series, and advanced authorship transparency with the CP2CT Publication Policy. < Conclusion: The CP2CT DECC has established a sustainable, scalable infrastructure that integrates administrative coordination, standardized data collection, robust program evaluation, and a collaborative learning environment. These efforts enhance clinical trial awareness, optimize referral pathways, and provide a transferable model for improving participant enrollment and scientific rigor across national research networks, ultimately addressing disparities in cancer outcomes. Citation Format: Laura E. Lectora, Cristina J. Orozco, Holly A. Thorson, Timethia Bonner, Robert R. Freimuth, Jennifer G. Le-Rademacher, Folakemi T. Odedina. Building a national network coordination center for clinical trials: Early implementation outcomes from the CP2CT DECC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 899.

Abstract Background: Multidisciplinary research networks often face challenges in harmonizing metrics and measures across participating sites, limiting the ability to aggregate data and generate generalizable insights. To address this barrier within the Connecting Patient Populations to Clinical Trials (CP2CT) Network, the Data, Evaluation, and Coordinating Center (DECC) coordinated the establishment of a unified framework that supports comparable evaluation and enhances the scientific impact of network-wide activities. Methods: Consensus was developed through a structured, iterative, and collaborative process: (1) drafting initial constructs, metrics, measures, and benchmarks informed by Network site materials and relevant literature; (2) soliciting qualitative and quantitative feedback from Network sites via Basecamp, an innovative online collaborative workspace for construct development; (3) conducting open dialogue sessions followed by systematic review and integration of site feedback; and (4) refining all elements through repeated feedback cycles until no further modifications were requested. Each iteration strengthened the clarity, coherence, and scientific precision of the final constructs. Results: A total of seven constructs were incorporated into the consensus-development process: clinical trials referral, clinical trials accrual, participants’ awareness of clinical trials, participants’ knowledge of clinical trials, providers’ awareness of NCI-supported clinical trials, providers’ engagement with NCI-supported clinical trials, and providers’ referral to NCI-supported clinical trials. For each construct, the Network established a conceptual definition (broad description of the construct), an operational definition (specification of how the construct is measured or observed), benchmarks (standards for assessing performance), metrics (quantitative indicators of performance), and measures (tools used to quantify inputs, processes, or outcomes). Common measures were developed for two constructs—clinical trials accrual and participants’ knowledge of clinical trials. Although full consensus was not achieved across all four Network sites for every construct, at least three sites reached consensus for the remaining five constructs. Conclusion: This consensus-building initiative resulted in the development of a unified, scientifically grounded framework. By harmonizing key elements related to clinical trial referral, accrual, awareness, knowledge, and provider engagement, the Network has established foundational tools that enable cross-site data comparability and facilitate more rigorous assessment of efforts to connect diverse patient populations to clinical trials. This framework positions the Network to inform strategies that improve equitable clinical trial participation. Citation Format: Folakemi T. Odedina, Jennifer Le-Rademacher, Robert Freimuth, Cristina Orozco, Laura Lectora, Timethia Bonner, Holly Thorson, Connecting Patient Populations to Clinical Trials(CP2CT) Program Evaluation Work Group, Connecting Patient Populations to Clinical Trials(CP2CT) Steering Committee. Development of and consensus building towards shared metrics, measures and benchmarks for the connecting patient populations to clinical trials (CP2CT) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 860.

Abstract Introduction: Attending to survivorship including distress in the contexts of social drivers (SDH) is critical but lacking. In response, this novel research on Black CaP survivors (CaPS) aims to measure SDH distresses and assess utility of a digital intervention to inform survivorship studies, practice and outcomes. Method: Informed by the Science of Survivorship, and our pilot study with multisectoral stakeholders, we assessed SDH and acceptability/utility of a digital Survivorship Care (SC) Toolkit. SCToolkit is a digitized whole-person care with guidance from multisectoral stakeholders e.g., clinicians and survivors. SCToolkit includes: ASCO informed treatment summary template for diagnostics, treatments, side effects, care team, genetics, and comorbidities, and patient active guide on survivorship concerns, provider communication, health advisories, survivorship care booklet, SDH FINDHELP resource, and survivorship videos. SCToolkit was delivered via survivors’ personal REDCap file, and can be uploaded to their EMR patient portal for easy-to-use survivorship roadmap accessible on smartphones, laptops, and computers. Motivational Interviewing was provided via Zoom to facilitate digital efficacy and SCToolkit use. Descriptive analyses were conducted using SAS. Citation Format: Kimlin Ashing, Floyd Willis, Christopher Williams, John McCall, Gaole Song, Douglas Adu-Fokuo, Erika Galdamez, Fornati Bedell, Cassandra N. Moore, EWAN COBRAN, Che Ngufor, Kathleen J. Yost, Timethia J. Bonner, Getachew Dagne, Arnold Merriweather, Ernest T. Kaninjing, Rotimi Oladapo, Roxana S. Dronca, Folakemi T. Odedina. Examining contextual distress and utility of a digital survivorship care toolkit [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 880.

Background: Understanding personal and geographic factors associated with smoking is important to design and implement interventions focused on reducing cancer health disparities. Scant research has been published recently regarding factors associated with smoking history associations within rural communities. Purpose: To examine demographic factors and rural residence history for associations with smoking history. Methodology: In a cross-sectional study of cancer-related behaviors, 1,786 adults (mean age 47.9 ± 17.5 years; 53% female, 84% White) completed an online survey in 2020. We examined factors associated with smoking history (having smoked at least 100 cigarettes) using independent t-tests, chi-square tests, and logistic regression. Results: Of the participants, 36% had a rural residence history and 49% had a smoking history. A larger proportion of men than women (61% vs. 37%; p < .001), White than Black participants (50% vs. 39%; p = .001), and rural than nonrural residents (53% vs. 46%; p = .005) had a smoking history. Logistic regression analysis revealed that the young age group (18–30) was less likely ( p = .002), whereas the middle age group (31–50) was more likely ( p < .001) to have a smoking history than those older than 50 years. Rural residence was associated with a smoking history among women ( p < .001), but not among men ( p = .70) in this sample. Conclusions: Tobacco control efforts are needed to focus on middle-aged men in general and women with rural residence history. Implications: Nurse practitioners are uniquely positioned to directly contribute to future research with self-identified rural populations that could help inform future public health policy.

Abstract Background In prostate cancer care, artificial intelligence (AI) models are increasingly used to generate personalized risk predictions by analyzing diverse data inputs, including clinical variables, imaging findings, and genomic indicators such as polygenic risk scores. However, effectively communicating these complex AI-derived risk estimates to patients presents significant challenges. Patients often struggle to understand probabilistic risk information, particularly when advanced algorithms generate it. Traditional cancer risk communication methods might not consider the complexities of AI outputs or differences in patient health literacy and numeracy. We propose a conceptual framework to guide patient-centered communication of AI-driven risk predictions. Methods We reviewed the existing literature on AI-based risk modeling, health risk communication, numeracy, dual-process information processing, and related theories to develop a communication framework designed explicitly for AI-based prostate cancer risk prediction tools. Results The proposed framework emphasizes clear, patient-specific risk communication strategies to enhance understanding and foster trust. It highlights a dual-process approach: offering intuitive visual aids and narrative explanations for quick, instinctive understanding, while also providing accurate statistics and explanations of the AI model’s reasoning for more deliberate processing. By addressing various patient numeracy levels and clearly explaining the AI model’s inputs, assumptions, and uncertainty in plain language, the framework aims to improve understanding and trust in AI-generated risk estimates. Additionally, to promote equity, it includes culturally responsive and accessible communication strategies tailored to patients’ linguistic, literacy, and cultural backgrounds. Conclusion This conceptual framework offers guidance on integrating AI-based risk prediction tools into prostate cancer consultations in a manner that is patient-friendly. By enhancing patients’ understanding of personalized risk information, building greater trust in AI-driven predictions, and addressing various communication needs, the framework helps facilitate more informed decision-making. Ultimately, patient-focused communication can help reduce disparities and promote more equity in prostate cancer care. Citation Format: Tingyu Zou, Folakemi Odedina. A Conceptual Framework for Communicating AI-Based Prostate Cancer Risk Predictions [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Prostate Cancer Research and Treatment; 2026 Jan 20-22; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86(2_Suppl):Abstract nr A083.